Early movers: LEN, MKC, YHOO, AAPL, CMG, VA, KERX, AMBA, EBAY & more

NYSE New York Stock Exchange traders markets
Getty Images

Check out which companies are making headlines before the bell:

Lennar — The home builder earned 63 cents per share for its latest quarter, beating estimates by 11 cents. Revenue was also above forecasts, as Lennar saw a 10 percent increase in new orders and a 12 percent rise in deliveries.

McCormick — The spice maker reported an adjusted quarterly profit of 74 cents per share, five cents above estimates, while revenue matched analyst forecasts. McCormick also said the negative impact of foreign currency will be less for 2016 than it had originally projected.

Yahoo — Yahoo has given possible suitors until Apr. 11 to submit bids for its assets, according to the Wall Street Journal. Yahoo is said to be shopping both the core web business and its stakes in Alibaba and Yahoo Japan.

Apple — Apple no longer faces legal action from the Justice Department, after officials said they were successful in unlocking an iPhone belonging to one of the San Bernardino shooters without the company's help.

Buffalo Wild Wings — Telsey upgraded the restaurant chain's stock to "outperform" from "market perform," saying it has confidence in management's strategy as well as an attractive valuation.

EBay, LinkedIn — Barclays downgraded both stocks, cutting eBay to "underweight" from "equal weight," and LinkedIn to "equal weight" from "overweight." It cites weak fundamentals for eBay, and a "decent period of consolidation" ahead for LinkedIn while investors try to figure out the business social network's future growth trajectory.

Ambarella — Morgan Stanley raised its rating on the maker of video processing chips to "overweight" from "equal-weight", pointing to expected growth in categories like wearables, drones, and automobiles, as well as new computer vision applications.

Chipotle Mexican Grill — Wedbush cut the restaurant chain's stock to "underperform" from "neutral," saying a sales recovery by 2018 is a best case scenario, not a base case outlook.

Keryx Pharmaceuticals — The drug maker reported a successful late stage clinical trial for its drug to treat iron deficiency anemia in certain kidney disease patients.

SunEdison — SunEdison faces an SEC probe over its liquidity disclosures to investors, according to the Wall Street Journal. The paper said the solar power company is being investigated over whether it overstated its liquidity in a disclosure to investors last fall. In a related story, SunEdison yieldco Terraform Global said the filing of its annual report will be delayed beyond Mar. 31, because of internal control weaknesses related to SunEdison's management services.

Virgin America — The airline's stock continues to be on watch today, after multiple reports Monday said JetBlue and Alaska Air were planning bids for their rival airline. Reuters is also reporting that various Asian airlines may also be interested in Virgin America.

Sears — Sears Chief Executive Officer Edward Lampert is buying some of the retailer's debt, according to Reuters. Lampert is said to have bought a portion of a new $750 million loan, which Sears is using to pay down some of its older debt.

Wells Fargo — Wells Fargo saw Warren Buffett's Berkshire Hathaway increase its ownership stake in the bank to 10 percent, according to an SEC filing, up from 9.8 percent on Dec. 31.

Foot Locker — Foot Locker will join the S&P 500 after the close of trading on Friday. The athletic footwear and apparel retailer will replace oilfield services company Cameron International, which is being acquired by Schlumberger. DCT Industrial Trust, a REIT specializing in industrial properties, will replace Foot Locker in the SK&P MidCap 400.

Wynn Resorts — Wynn shares are rising as a court battle escalates between founder Steve Wynn and ex-wife Elaine Wynn. She is accusing Steve Wynn of reckless behavior and engineering her ouster from the casino operator's board.

Affymetrix — Origin Technologies withdrew its $17 per share offer for Affymetrix after the maker of gene-sequencing products rejected its bid. Affymetrix already has a deal in place to be acquired by Thermo Fisher Scientific, and said there is too much risk in the Origin deal despite a price that's three dollars per share higher. Origin – which is owned by former Affymetrix employees, said it was disappointed and that it disagreed with that assessment of perceived risks.

Questions? Comments? Email us at marketinsider@cnbc.com